Therefore, for elderly patients with advanced NSCLC aged 75 and above, it is necessary to strictly evaluate the patient's PD-L1 expression level, physical condition (such as PS score), organ function, and comorbidities, and closely monitor adverse reactions to select the appropriate treatment plan. The gene discussed is CD274; the disease is non-small cell lung carcinoma.